UBS’s wedding to Credit Suisse — with Thomas Jordan holding the shotgun — puts the nail in the coffin of investing certainty.
Following the turmoil at Credit Suisse, markets have rebounded.
Asian markets experienced a rebound overnight from the previous day’s downturn, as concerns about another financial crisis eased and lenders were lifted.
According to the Financial Times, UBS has agreed to acquire Credit Suisse for a sum exceeding $2 billion.
As per the Financial Times report on Sunday, UBS (UBSG.S) has raised its offer to more than $2 billion to acquire the Swiss banking behemoth Credit Suisse (CSGN.S).
What the hell is going on? Silicon Valley Bank, First Republic, Credit Suisse & potentially hundreds more
Good morning investors, and welcome to my very first newsletter on Substack. I have been motivated to start this weekly transmission for a few reasons.
As concerns about banking contagion escalate, UBS is considering a possible acquisition of Credit Suisse.
Sources have reported that UBS AG (UBSG.S) is considering the acquisition of Credit Suisse (CSGN.S), its struggling Swiss counterpart, in an effort to prevent the ongoing crisis at the bank
Credit Suisse sued by U.S shareholders
Credit Suisse’s recent troubles have led to its first lawsuit by US investors, who claim that the bank exaggerated its financial prospects to shareholders.
Bank stocks are experiencing a decline as Credit Suisse’s actions trigger concerns of a new crisis.
As Credit Suisse’s largest shareholder rules out injecting additional funds into the troubled lender, concerns over the banking sector have deepened, leading to a decline in the stock markets.
Poolbeg Pharma PLC (AIM:POLB) POLB 001 patent portfolio strengthened
POLB 001 patent portfolio strengthened through granting of US patent
Poolbeg Pharma Plc (AIM:POLB) Positive Results from POLB 001 LPS Human Challenge Trial
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza
Vela Technologies (AIM:VELA) Quarterly Investment Update
The Board of Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, is pleased to report an update for the quarter ended 31 December 2022.
Poolbeg Pharma PLC (AIM:POLB) Strategic expansion of POLB 001 into oncology
Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications.
Poolbeg Pharma PLC (AIM:POLB) Positive Initial Data Analysis in POLB 001 Trial
Early data readout indicates a successful LPS human challenge trial